ACTON, Mass., June 22, 2016 /PRNewswire/ -- Psychemedics
Corporation (NASDAQ: PMD) announced that James P. Abely has joined the company as
Associate General Counsel.
In this important role, Jim will be responsible for directing
and managing all of the company's legal activities, including
working closely with the company's clients. He will report to
the company's CEO. Jim practiced law with the Boston firm of Goodwin Procter LLP following
his graduation from the University of
Virginia School of Law. His strong litigation background
will be most helpful to Psychemedics and its clients.
Raymond C. Kubacki, Chairman and
CEO of Psychemedics, stated, "We are extremely pleased to have Jim
joining our team and heading up this important area in our company.
Besides providing our clients with the most vigorous drug test
available and outstanding client service, we also directly support
our clients on any legal challenge. We not only provide a
litigation packet and expert testimony, but also legal assistance
for our client's legal team to come up to speed quickly.
That's why this is such an important role in our company and beyond
the normal role of Associate General Counsel."
Psychemedics Corporation is the world's largest provider of hair
testing for the detection of drugs of abuse. The Company's patented
process is used by thousands of U.S. and international clients,
including over 10% of the Fortune 500 companies, for pre-employment
and random drug testing. Major police departments, Federal Reserve
Banks, schools, and other public entities also rely on our unique
patented drug testing process. We strongly believe our drug testing
method to be superior to any other product currently in use,
including traditional urine testing and other hair testing
methods.
The Psychemedics web site is www.psychemedics.com
Cautionary Statement for purposes of the "safe harbor"
provisions of the Private Securities Litigation Reform Act of
1995: From time to time, information provided by Psychemedics
may contain forward-looking information that involves risks and
uncertainties. In particular, statements contained in this
release that are not historical facts (including but not limited to
statements concerning earnings, earnings per share, revenues, cash
flows, dividends, future business, growth opportunities (including
an opportunity in Brazil), new
accounts, customer base, market share, test volume, sales and
marketing strategies, U.S. and foreign drug testing laws and
regulations including effective dates thereof, required investments
in plant, equipment and people and new test development) may be
"forward looking" statements. Actual results may differ from
those stated in any forward-looking statements. Factors that
may cause such differences include but are not limited to risks
associated with the development of markets for new products and
services offered, costs of capacity expansion, U.S. and foreign
government regulation, including but not limited to FDA
regulations, Brazilian laws and regulations and projected
implementation dates, proposed laws and regulations, R&D
spending, competition (including, without limitation, competition
from other companies pursuing the same growth
opportunities) and general economic conditions and other
factors disclosed in the Company's filings with the Securities and
Exchange Commission. Information regarding testing volume for
a partial quarter may not necessarily be an indicative of results
to be expected for the full quarter or year. The forward-looking
statements contained herein speak only of the Company's
expectations as of the date of this press release. The
Company expressly disclaims any obligation or undertaking to
release publicly any updates or revisions to any such statement to
reflect any change in the Company's expectations or any change in
events, conditions, or circumstances on which any such statement is
based.
Contact:
Raymond C. Kubacki
Chairman, President and CEO
(978) 206-8220
Logo -
http://photos.prnewswire.com/prnh/20111107/NE00639LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/james-p-abely-joins-psychemedics-corporation-as-associate-general-counsel-300288685.html
SOURCE Psychemedics Corporation